Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

129
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
129
Development of Immunocompetence01:22

Development of Immunocompetence

1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.7K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microsecond dynamics control the HIV-1 Envelope conformation.

Science advances·2024
Same author

Discovery and Characterization of a Pan-betacoronavirus S2-binding antibody.

bioRxiv : the preprint server for biology·2024
Same author

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates.

bioRxiv : the preprint server for biology·2024
Same author

Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques.

Cell·2024
Same author

Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies.

bioRxiv : the preprint server for biology·2024
Same author

Engineered immunogens to elicit antibodies against conserved coronavirus epitopes.

Nature communications·2023

Related Experiment Video

Updated: Apr 25, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

9.6K

Progress in HIV-1 vaccine development.

Barton F Haynes1, M Anthony Moody2, Munir Alam3

  • 1Duke Human Vaccine Institute, Durham, NC; Department of Medicine, Duke University School of Medicine, Durham, NC; Department of Immunology, Duke University School of Medicine, Durham, NC.

The Journal of Allergy and Clinical Immunology
|August 14, 2014
PubMed
Summary

Developing an effective HIV-1 vaccine faces challenges despite recent scientific advances. New targets and strategies show promise, but significant roadblocks remain for successful vaccine candidates.

Keywords:
B cellsHIV-1T cellsbroadly neutralizing antibodiesvaccine

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.0K
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

13.8K

Related Experiment Videos

Last Updated: Apr 25, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

9.6K
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.0K
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

13.8K

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Recent years have yielded significant basic and translational science progress in HIV-1 vaccine development.
  • Key advances include identifying novel envelope targets for protective antibodies and understanding CD8(+) T cell roles in controlling HIV-1.

Purpose of the Study:

  • To review recent scientific advances in HIV-1 vaccine research.
  • To identify remaining roadblocks and promising approaches for successful HIV-1 vaccine candidates.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Analysis of immunological and virological findings related to HIV-1 vaccine development.

Main Results:

  • Advances include new antibody targets, CD8(+) T cell control demonstration, immunogen development for epitope diversity, identification of transmission risk correlates, and mapping of coevolution pathways for neutralizing antibodies.
  • A 2013 HIV-1 vaccine efficacy trial did not prevent infection, indicating continued challenges.

Conclusions:

  • Despite progress, an effective HIV-1 vaccine is still years away.
  • Promising approaches focus on overcoming HIV-1 T-cell epitope diversity and understanding neutralizing antibody pathways.
  • Continued research into novel targets and strategies is crucial for advancing HIV-1 vaccine candidates.